Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche’s Flu MedKit Seeks “Alternate Pathway” For OTC Drugs

This article was originally published in The Tan Sheet

Executive Summary

The antiviral drug home stockpiling MedKit being shepherded by the Department of Health and Human Services could be the first product to test FDA's stated interest in "creative paths to access" that straddle or depart from the traditional choice of Rx or OTC status
Advertisement

Related Content

MedKit Development For Flu Outbreak Is “Part Of The Discussion”– Sharfstein
MedKit Development For Flu Outbreak Is “Part Of The Discussion”– Sharfstein
MedKit Development For Flu Outbreak Is “Part Of The Discussion”– Sharfstein
FDA Would Ease AER Requirements During Flu Pandemic
FDA Would Ease AER Requirements During Flu Pandemic
FDA Would Ease AER Requirements During Flu Pandemic
FDA Panel To Influenza Home MedKit Sponsors: Get Real
FDA Panel To Influenza Home MedKit Sponsors: Get Real
Behind-The-Counter Guidance Stalled, But Interest Grows To Expand Access
BTC Proponents Cite Pharmacists’ Role; Opponents Question Need

Topics

Advertisement
UsernamePublicRestriction

Register

PS102363

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel